Last reviewed · How we verify
JE-VAX®
JE-VAX is a live attenuated vaccine that stimulates immune response against Japanese encephalitis virus.
JE-VAX is a live attenuated vaccine that stimulates immune response against Japanese encephalitis virus. Used for Prevention of Japanese encephalitis in endemic regions.
At a glance
| Generic name | JE-VAX® |
|---|---|
| Sponsor | Sanofi |
| Drug class | Live attenuated vaccine |
| Modality | Biologic |
| Therapeutic area | Infectious Disease / Immunology |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains a weakened strain of Japanese encephalitis virus that triggers both humoral and cellular immune responses without causing disease. This allows the body to develop protective antibodies and T-cell immunity against the virus, preventing infection or reducing disease severity upon exposure to wild-type virus.
Approved indications
- Prevention of Japanese encephalitis in endemic regions
Common side effects
- Injection site reactions (pain, erythema, swelling)
- Fever
- Myalgia
- Headache
Key clinical trials
- A Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis Messenger Ribonucleic Acid (mRNA) Vaccines (GBP560) in Healthy Adults (PHASE1, PHASE2)
- A Phase 1, First-in-human, Double-blinded, Randomized, Placebo-controlled Trial of a Zika Virus Purified Inactivated Vaccine (ZPIV) With Alum Adjuvant in Healthy Flavivirus-naive and Flavivirus-Primed Subjects. (PHASE1)
- Safety and Immunogenicity of the Japanese Encephalitis Vaccine IC51 (IXIARO®) in a Pediatric Population (PHASE3)
- Immunogenicity and Safety of the Japanese Encephalitis Vaccine IC51 (IXIARO®, JESPECT®) in a Pediatric Population in Non-endemic Countries (PHASE3)
- Long Term Immunity and Safety Following Vaccination With the JEV IC51 (IXIARO®, JESPECT®) in Pediatric Population In Non Endemic Countries. Uncontrolled, Ph3 FU-Study (PHASE3)
- Immune Responses After a Booster Immunisation With IXIARO® in Elderly Compared to Young Individuals. (PHASE4)
- Safety and Immunogenicity of Formulations of Dengue Vaccines in Healthy Flavivirus-Naïve Adults (PHASE2)
- Open-label, Randomized Study in a Pediatric Population in a JEV (Japanese Encephalitis Virus)-Endemic Country (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- JE-VAX® CI brief — competitive landscape report
- JE-VAX® updates RSS · CI watch RSS
- Sanofi portfolio CI